A phase 1b/2a, multi-center, open-label study to evaluate the safety and efficacy of combination treatment with MEDI0457 (INO-3112) and durvalumab (MEDI4736) in patients with recurrent/metastatic human papilloma virus–associated head and neck squamous cell cancer.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Hospital of the University of Pennsylvania, Albert Einstein College of Medicine, Wake Forest Baptist Comprehensive Cancer Center, Emory University, Winship Cancer Institute, The Barbara Ann Karmanos Cancer Institute, Indiana University Indianapolis, Johns Hopkins Hospital, Washington University in St. Louis, Rush University Medical Center, University of Chicago, Morristown Medical Center, Atlantic Health System
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2889801048